Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. 2006 Mars, J Clin Microbiol ,
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci ,
, J Clin Microbiol
,
Investigation of Linezolid Resistance in Staphylococci and Enterococci, J Clin Microbiol, 2016. ,
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci ,
, J Clin Microbiol
Linezolid: pharmacokinetic characteristics and clinical studies, Clinical Microbiology and InfectionVolume, vol.7, pp.75-82, 2001. ,
Age and sex effects on the pharmacokinetics of linezolid, Eur J Clin Pharmacol, 2002. ,
Intrapulmonary pharmacokinetics of linezolid, Antimicrob Agents Chemother, 2002. ,
Linezolid absolute bioavailability and the effect of food on oral bioavailability, Biopharm Drug Dispos, 2001. ,
,
, Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects, Drug Metab Dispos, 2001.
Pharmacokinetics of linezolid in subjects with renal dysfunction, 2003. ,
, Antimicrob Agents Chemother
Pharmacokinetics of linezolid in patients with liver disease, Antimicrob Agents Chemother, 1999. ,
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, Antimicrob Agents Chemother, 1996. ,
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections, J Antimicrob Chemother, 2003. ,
, Drugs, 2000.
Post-antibiotic growth suppression of linezolid against Gram-positive bacteria, 2001. ,
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU 100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium, Antimicrob Agents Chemother, 1998. ,
In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected Gram-negative organisms, Antimicrob Agents Chemother, 2003. ,
In vitro activities of quinupristindalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrugresistant staphylococci and enterococci in and in vitro pharmacodynamic model, Antimicrob Agents Chemother, 2002. ,
In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2005. ,
In vitro and in vivo assessment of linezolid combined with ertapenem : a highly synergistic combination against methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2006. ,
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus, Antimicrob Agents Chemother, 2003. ,
In vitro activity of fosfomycin in combination with various antistaphylococcal substances, 2001. ,
In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by timekill curve methods, J Antimicrob Chemother, 2003. ,
Oxazolidinone structure-activity relationships leading to linezolid, Angew Chem Int Ed Engl, 2003. ,
The Oxazolidinone Eperezolid Binds to the 50S Ribosomal Subunit and Competes with Binding of Chloramphenicol and Lincomycin, Antimicrob Agents Chemother, 1997. ,
Mechanism of Action of Oxazolidinones: Effects of Linezolid and Eperezolid on Translation Reactions, Antimicrob Agents Chemother, 1997. ,
Resistance Mutations in 23 S rRNA Identify the Site of Action of the Protein Synthesis Inhibitor Linezolid in the Ribosomal Peptidyl Transferase Center, J. Mol. Biol, 1999. ,
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria, Antimicrob Agents Chemother, 1998. ,
,
, Oxazolidinone Antibiotics Target the P Site on Escherichia coli Ribosomes, 2002.
Activity of Linezolid against Gram-positive cocci possessing genes conferring resistance to proteins synthesis inhibitors, Journal of Antimicrobial Chemotherapy, 2000. ,
Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid, Journal of Antimicrobial Chemotherapy, 2002. ,
Subinhibitory Concentrations of Linezolid Reduce Staphylococcus aureus Virulence Factor Expression, Antimicrob Agents Chemother, 2004. ,
Linezolid : pharmacokinetic characteristics and clinical studies ,
, Clin Microbiol Infect, 2001.
The oxazolidinones as a new family of antimicrobial agent, Clin Microbiol Infect, 2001. ,
, Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program, 2005.
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations, 2006. ,
,
Linezolid: a promising option in the treatment of Gram-positives, J Antimicrob Chemother, 2016. ,
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus ,
, J Antimicrob Chemother
In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods, J Antimicrob Chemother, 2001. ,
In vitro activity of linezolid against multiply resistant Grampositive clinical isolates, J Antimicrob Chemother, 2001. ,
Comparative in vitro activities of linezolid, quinupristindalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible andresistant streptococci, Antimicrob Agents Chemother, 2000. ,
In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species, Diagn Microbiol Infect Dis, 2002. ,
In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 Grampositive anaerobic and 31 Corynebacterium clinical isolates, Antimicrob Agents Chemother, 2003. ,
Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Grampositive species, Actinomycetes, and Lactobacilli, Antimicrob Agents Chemother, 2005. ,
Susceptibilities of Legionella spp. to newer antimicrobials in vitro, Antimicrob Agents Chemother, 1998. ,
In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis, Antimicrob Agents Chemother, 2004. ,
In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods, J Antimicrob Chemother, 2001. ,
Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones, Antimicrob Agents Chemother, 2001. ,
Linezolid (ZYVOX), the First Member of a Completely New Class of ,
, Antibacterial Agents for Treatment of Serious Gram-Positive Infections, J. Med. Chem, 2008.
In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model, Antimicrob Agents Chemother, 2002. ,
Efficacy of linezolid in a staphylococcal endocarditis rabbit model, J Antimicrob Chemother, 2001. ,
Efficacy of linezolid i n treatment of experimental endocarditis caused by methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2001. ,
Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid, J Infect, 2006. ,
Infective endocarditis treated with linezolid : case report and literature review, Eur J Clin Microbiol Infect Dis, 2006. ,
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs, Antimicrob Agents Chemother, 2003. ,
Linezolid for the treatment of multidrug-resistant tuberculosis, J Antimicrob Chemother, 2005. ,
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis, J Antimicrob Agents, 2002. ,
The discovery of linezolid, the first oxazolidinone antibacterial agent, Curr Drug Targets Infect Disord, 2001. ,
Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from German hospital patients, J. Glob. Antimicrob. Resist, 2015. ,
Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms, Drug resistance Updates ,
ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries, J. Antimicrob. Chemother, 2017. ,
Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program, 2011. ,
,
, Korea: low rate of 23S rRNA mutations in Enterococcus faecium, 2017.
Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis, Antimicrob Agents Chemother, 2003. ,
, Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis, 2002.
Experimental dose regimen modelling of intestinal emergence of Enterococcus faecalis resistant to linezolid in gnotobiotic mice, 2006. ,
Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis, Antimicrob Agents Chemother, 2002. ,
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin, Antimicrob Agents Chemother, 2009. ,
Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms, J. Antimicrob. Agents, 2013. ,
Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase, J Clin Microbiol, 2008. ,
A substrate radical intermediate in catalysis by the antibiotic resistance protein Cfr, Nat Chem Biol, 2013. ,
Acquisition of a natural resistance gene renders a clinical strain of methicillinresistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, 2007. ,
,
The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A, 2006. ,
Detection of a cfr(B) variant in german Enterococcus faecium clinical isolates and the impact on linezolid resistance in Enterococcus spp, PLoS One, 2016. ,
Investigation of a multiresistance gene cfr that fails to mediate resistance to phenicols and oxazolidinones in Enterococcus faecalis, J. Antimicrob. Chemother, 2014. ,
A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin, J. Antimicrob. Chemother, 2015. ,
Detection in Italy of two clinical Enterococcus faecium isolates carrying both the oxazolidinone and phenicol resistance gene optrA and a silent multiresistance gene cfr, J. Antimicrob. Chemother, 2016. ,
Antibiotic resistance ABC-F proteins: bringing target protection into the limelight, 2018. ,
, Molecular Epidemiology and Mechanisms of 43 Low-Level Linezolid-Resistant Enterococcus faecalis Strains in, 2018.
Characterization of poxtA, a novel phenicoloxazolidinone-tetracycline resistance gene from an MRSA of clinical origin, J. Antimicrob. Chemother, vol.81, 2018. ,
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard, CLSI (NCCLS), vol.26, pp.7-7, 2006. ,
Détermination de la sensibilité aux antibiotiques ,
, , p.6, 2018.
Tableaux des concentrations critiques pour l'interprétation des CMI et des diamètres critiques des zones d'inhibition ,
, , pp.70-77, 2018.
, Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in, 2010.
Linezolid resistance in a clinical isolate of Staphylococcus aureus, Lancet, 2001. ,
,
Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis, Antimicrob Agents Chemother, 2012. ,
Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance, Eur J Clin Microbiol Infect Dis, 2017. ,
Nosocomial enterococci resistant to vancomycin--United States, 1989. ,
Spectrum and potency evaluation of a new oxazolidinone, linezolid : report from the SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis, 1998. ,
Surveillance for linezolid resistance via the Zyvox ® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates, Journal of Antimicrobial Chemotherapy, vol.71, issue.7, 2016. ,
, Centre National des Staphylocoques, Rapport annuel d'activité, 2017.
, Centre National des entérocoques, Rapport d'activité, 2018.